FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology

Table 1

Increased serum FGF21 levels in metabolic disease patients with insulin resistance.

Disease	Insulin signaling	Serum FGF21 levels
Nonalcoholic fatty liver disease	Resistance	Increase
Type 2 diabetes	Resistance	Increase
Obesity	Resistance	Increase
Cushing’s syndrome	Resistance	Increase
Lipodystrophy induced by HIV-1	Resistance	Increase
Endostage renal disease	Resistance	Increase